Industry
Biotechnology
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Loading...
Open
2.75
Mkt cap
271M
Volume
145K
High
2.80
P/E Ratio
-4.41
52-wk high
4.27
Low
2.65
Div yield
N/A
52-wk low
1.87
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 1:14 pm
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 8:17 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 8:39 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Insights
June 11, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 10:10 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 3:51 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:26 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.